Mylan Pharma UK Ltd. clinical trials
Acquired by Viatris Inc., Nov 16, 2020 · source ↗
The registry lists 5 studies whose lead sponsor is Mylan Pharma UK Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 1, 2024.
Before and after it joined Viatris Inc.
- First submitted before Mylan Pharma UK Ltd. became part of Viatris Inc.
- 3
- First submitted after Mylan Pharma UK Ltd. became part of Viatris Inc.
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Mylan Pharma UK Ltd.5 studies
Something wrong with this grouping? Tell us on the Viatris Inc. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Viatris Inc. studies →
- Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT05046795Phase 3
Sponsor listed in the registry: Mylan Pharma UK Ltd. · First submitted after Mylan Pharma UK Ltd. became part of Viatris Inc.
- Fasting Bioavailability Study of Mylan's Revefenacin Inhalation SolutionCompletedNCT05207111Phase 1
Sponsor listed in the registry: Mylan Pharma UK Ltd. · First submitted after Mylan Pharma UK Ltd. became part of Viatris Inc.
- Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIsCompletedNCT02215122Phase 1
Sponsor listed in the registry: Mylan Pharma UK Ltd. · First submitted before Mylan Pharma UK Ltd. became part of Viatris Inc.
- An Open Study to Assess the Robustness of the CRC749 InhalerCompletedNCT02474017Phase 1
Sponsor listed in the registry: Mylan Pharma UK Ltd. · First submitted before Mylan Pharma UK Ltd. became part of Viatris Inc.
- MGR001 / Advair Diskus Local Equivalence Study in AsthmaCompletedNCT02245672Phase 3
Sponsor listed in the registry: Mylan Pharma UK Ltd. · First submitted before Mylan Pharma UK Ltd. became part of Viatris Inc.